Reminder: Expert Access: Barclays Hosted KOL Lunch at AAIC 2026: Diving into CELIA Data and Other Alzheimer’s Updates

Research evidence excerpt

Reminder: Expert Access: Barclays Hosted KOL Lunch at AAIC 2026: Diving into CELIA Data and Other Alzheimer’s Updates

Relevant Research:

•• Biogen Inc.: Oh CELIA...not quite breaking our hearts, but shaking our confidence (maybe)

(05/14/26)

•• Global Biopharma: Alzheimer's Disease KOL Call Prep Pack (06/11/26)

•• BIIB/LLY/BMY: Barclays Alzheimer's KOL Call: US takeaways (06/11/26)

Meet the Speaker

Dr. Marc Gordon is the Chief of Neurology at Northwell Health's Zucker Hillside Hospital

and a Professor of Neurology and Psychiatry at the Donald and Barbara Zucker School of

Medicine at Hofstra/Northwell. Dr. Gordon's primary subspecialty interest is in behavioral

neurology and neuropsychiatry, and he treats 125 Alzheimer's patients annually. He has

been a principal investigator in clinical research studies of Alzheimer's disease, mild

cognitive impairment, and vascular dementia. His current research involves clinical trials

for novel medications, biomarker studies, and imaging techniques. Dr. Gordon received his

MD from Columbia University.

Meet the Analysts

Emily Field, CFA is a Director and Head of U.S.

Biopharmaceuticals equity research at Barclays. Joining

the bank’s London office in 2017, she previously served as

Head of the European Pharmaceuticals team, earning a #4

individual ranking in European Pharmaceuticals &

Biotechnology in the 2025 Extel survey. With more than

two decades experience across both buy-side and sell-side

roles, she has worked across multiple investing strategies

including risk arbitrage and equity long/short. Prior to

Barclays, Ms. Field held positions at UBS O’Connor and

Millennium Management. Originally hailing from Chicago,

Ms. Field holds a B.A. in Economics and History from Yale

University, graduating with distinction in both majors, and